Eli Lilly Spent $25 Billion on Deals This Year. Guess Where All That Cash Went.

Then there's Kelonia Therapeutics, an in vivo gene delivery company that Lilly scooped up for up to $7 billion. The venture firm Venrock had backed Kelonia, and Bryan Roberts of Venrock said the deal earned his firm at least a 45x return. Let that sink in. For every dollar Venrock put in, they got $45 back. That's not a good investment; that's a generational one.

The list keeps going. Orna Therapeutics (circular RNA and cell therapy) went for up to $2.4 billion. Ajax Therapeutics (blood cancer drugs) fetched up to $2.3 billion. Lilly even went on a vaccine shopping spree, picking up Curevo, LimmaTech Biologics, and a company literally called Vaccine Company for a combined value of roughly $3.8 billion. Smaller deals like Ventyx Biosciences ($1.2 billion, inflammation) and CrossBridge Bio ($300 million, oncology) rounded out the portfolio.

The Capital Flywheel Nobody Talks About

Here's where the story gets interesting beyond Lilly itself. When a pharma giant writes a multi-billion-dollar check to buy a startup, that money doesn't just sit still. It cycles.

The VCs who earned those returns? They use that cash to raise new funds. Those new funds back new startups. Some of those startups will eventually get acquired, too, restarting the whole process. Biotech people call this the "capital flywheel," and in 2026, Lilly is practically the main engine spinning it.

The numbers across the broader industry support this. J.P. Morgan reported $96 billion in biopharma M&A during the first half of 2026, up from $42.3 billion in the same period a year earlier. That liquidity is feeding venture activity: biotech companies raised more than $9.1 billion in venture funding during H1 2026, with about 76% of that coming from megarounds north of $100 million.

Experienced founders and scientists from acquired companies are also getting released back into the wild, often to start new ventures. It's like a biotech diaspora, except everyone leaves with cash and connections.

The Catch: Not Everyone Gets a Ticket

Before you picture a rising tide lifting all biotech boats, there's a catch. The capital recycling effect is selective, not universal.

About two-thirds of venture rounds in early 2026 went to companies that already had a drug in human testing. First financings (the earliest checks into brand-new startups) accounted for only 26% of total capital, even though they represented 36% of deals. Translation: new companies are forming, but the really big checks are going to later-stage bets with real clinical data.

This makes intuitive sense. When a VC just earned 45x on a late-stage acquisition, they're going to look for the next company that fits that same profile: strong science, human proof-of-concept, clear path to a buyer. The tiny, pre-clinical, "trust us, the biology is cool" startups have a harder time competing for attention.

S&P Global found that the total number of U.S. biotech venture rounds actually fell 25.2% year over year in early 2026, even as total dollar volume stayed relatively high. Fewer deals, bigger checks. The barbell is getting more extreme.

What This Means for the Next Chapter

Lilly's 2026 deal spree is more than a corporate strategy story. It's a case study in how one company's appetite can reshape an entire ecosystem.

Venture firms just got paid. That capital will find its way into new funds, new startups, and new scientific bets over the next few years. The talent from acquired companies will scatter and build again. And other pharma companies are watching closely; if Lilly can use its GLP-1 cash to build a diversified pipeline through M&A, why can't they?

But the pattern also reinforces a hard truth about biotech in 2026. The system rewards companies that can generate clinical data and position themselves as acquisition targets. If you're a scrappy seed-stage startup without human data, the flywheel is spinning, but it might not be spinning for you.

The money is flowing. It's just not flowing everywhere equally.

Arsenal Bio Just Torched Its Own Playbook. Here's Why.

Arsenal Biosciences just fired 99 employees, killed its clinical programs, and bet everything on a technology that barely exists in the clinic. When a company backed by $630 million torches its own playbook, it tells you something important about where cell therapy is headed.